Biomarkers in Breast Cancer-microRNA profiling and Omics analysis
Not Applicable
- Conditions
- Health Condition 1: C50- Malignant neoplasm of breast
- Registration Number
- CTRI/2024/01/061792
- Lead Sponsor
- Government Mohan Kumaramangalam Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Consecutive patients with newly detected breast cancer- planned for surgery (MRM or BCT) or Neo-adjuvant chemotherapy
2.Age and sex-matched subjects without breast cancer
Exclusion Criteria
1.Known case of Breast cancer previously treated with surgery, chemotherapy or radiotherapy
2.Previous history of treatment for non-breast cancer
3.Patients with unsound mind
4.Patients not willing
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Diagnostic microRNA in breast cancer patients versus healthy adults such as miR-16, miR-19b, miR-106a, miR-21, miR-1246, miR-939, miR-373, miR-101, miR155, let-7 family of miR125b, miR100, miR34a, miR-335 <br/ ><br>2. Prognostic microRNA in Breast Cancer such as miR-16, miR-19b, miR-106a, miR-21, miR-1246, miR-939, miR-373, miR-101, miR155, let-7 family of miR125b, miR100, miR34a, miR-335Timepoint: 1. Early Breast Cancer <br/ ><br>Before Surgery <br/ ><br>Before Adjuvant Chemotherapy <br/ ><br>Before Adjuvant Radiotherapy <br/ ><br>3-month post-chemoradiotherapy <br/ ><br>2.Locally Advanced Breast cancer <br/ ><br>Before neoadjuvant therapy <br/ ><br>Before Surgery <br/ ><br>Before Adjuvant Chemotherapy <br/ ><br>Before Adjuvant Radiotherapy <br/ ><br>3-month post-CRT <br/ ><br>3. Metastatic Breast Cancer <br/ ><br>Before and after palliative therapy <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method microRNA (miR) profile- Early BC markers-miR-16 and miR-106a, a miR-19b-based 3-circulating miRNA <br/ ><br>miR profile - Invasive Breast Cancer-miR-12, miR-1246 <br/ ><br>miR profile- Triple negative breast cancer-miR-939 <br/ ><br>miR profile- Drug resistance - miR-451, miR-326, miR- 100, miR-222, and miR- 30a <br/ ><br>miR profile- Poor prognosis- miR-155, miR-21, miR-1246, miR-let 7 family <br/ ><br>miR profile- Diagnostic versus Prognostic markers- miR 155, miR-let 7 family <br/ ><br>Timepoint: 1. Early Breast Cancer <br/ ><br>Before Surgery <br/ ><br>Before Adjuvant Chemotherapy <br/ ><br>Before Adjuvant Radiotherapy <br/ ><br>3-month post-chemoradiotherapy <br/ ><br>2.Locally Advanced Breast cancer <br/ ><br>Before neoadjuvant therapy <br/ ><br>Before Surgery <br/ ><br>Before Adjuvant Chemotherapy <br/ ><br>Before Adjuvant Radiotherapy <br/ ><br>3-month post-CRT <br/ ><br>3. Metastatic Breast Cancer <br/ ><br>Before and after palliative therapy <br/ ><br> <br/ ><br>